The estimated Net Worth of Joseph Mannello is at least $1.46 Milion dollars as of 31 March 2020. Mr. Mannello owns over 16,529 units of MYOS RENS Technology stock worth over $1,401,433 and over the last 9 years he sold MYOS stock worth over $0. In addition, he makes $63,356 as Chief Executive Officer i Director at MYOS RENS Technology.
Sign up
Mr. Mannello MYOS stock SEC Form 4 insiders trading
Joseph has made over 9 trades of the MYOS RENS Technology stock since 2016, according to the Form 4 filled with the SEC. Most recently he bought 16,529 units of MYOS stock worth $16,694 on 31 March 2020.
The largest trade he's ever made was buying 681,818 units of MYOS RENS Technology stock on 5 March 2020 worth over $825,000. On average, Joseph trades about 84,668 units every 104 days since 2016. As of 31 March 2020 he still owns at least 1,387,557 units of MYOS RENS Technology stock.
You can see the complete history of Mr. Mannello stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Joseph Mannello biography
Joseph Mannello serves as Chief Executive Officer, Director of the Company. He served as our interim Chief Executive Officer from September 2016 until August 2017 and as a director since December 2015. From May 2015 to September 2016, he served as a consultant for Brean Capital, LLC. an independent investment bank and asset management firm. From March 2013 to May 2015, he served as the executive managing director at Brean Capital LLC, where he also served as a member of the firm’s operating committee. From March 2008 to March 2012, Mr. Mannello was the head of corporate credit for Gleacher & Company, Inc. (OTC:GLCH), a publicly-traded investment bank. Prior to that, he was the head of the fixed income division of BNY Capital Markets, Inc., a subsidiary of The Bank of New York Mellon Corp. (NYSE:BK).
What is the salary of Joseph Mannello?
As the Chief Executive Officer i Director of MYOS RENS Technology, the total compensation of Joseph Mannello at MYOS RENS Technology is $63,356. There are no executives at MYOS RENS Technology getting paid more.
How old is Joseph Mannello?
Joseph Mannello is 62, he's been the Chief Executive Officer i Director of MYOS RENS Technology since 2017. There are 2 older and 5 younger executives at MYOS RENS Technology. The oldest executive at MYOS RENS Technology, Inc. is Christopher Dewey, 75, who is the Independent Director.
What's Joseph Mannello's mailing address?
Joseph's mailing address filed with the SEC is C/O MYOS RENS TECHNOLOGY INC., 45 HORSEHILL ROAD, SUITE 106, CEDAR KNOLLS, NJ, 07927.
Insiders trading at MYOS RENS Technology
Over the last 12 years, insiders at MYOS RENS Technology have traded over $0 worth of MYOS RENS Technology stock and bought 2,115,845 units worth $2,654,259 . The most active insiders traders include David J Matlin, Christopher Pechock oraz Joseph Mannello. On average, MYOS RENS Technology executives and independent directors trade stock every 78 days with the average trade being worth of $59,361. The most recent stock trade was executed by Joseph Mannello on 31 March 2020, trading 16,529 units of MYOS stock currently worth $16,694.
What does MYOS RENS Technology do?
MYOS RENS Technology, Inc. operates as a nutrition company, develops and markets products that improve muscle health and performance. Its primary product is Fortetropin, a proprietary bioactive composition derived from fertilized egg yolk, intended to increase lean muscle mass, size, and strength. The company was founded on April 11, 2007 and is headquartered in Cedar Knolls, NJ.
What does MYOS RENS Technology's logo look like?
Complete history of Mr. Mannello stock trades at MYOS RENS Technology
MYOS RENS Technology executives and stock owners
MYOS RENS Technology executives and other stock owners filed with the SEC include:
-
Joseph Mannello,
Chief Executive Officer, Director -
Robert Hariri,
Independent Chairman of the Board -
Eric Zaltas,
Independent Director -
Andrew Ponte,
Independent Director -
Christopher Pechock,
Independent Director -
Victor Mandel,
Independent Director -
Christopher Dewey,
Independent Director -
Louis Aronne,
Independent Director -
Ren Ren,
Director -
Sapna Srivastava,
Director -
Joseph Dos Santos,
Chief Financial Officer -
Kenrick Bryce Toussaint,
Chief Executive Officer -
Buzz Aldrin,
Director -
Zhengguang Lyu,
Director -
Robert C. Jr. Ashton,
Chief Medical Officer -
Peter Diamandis,
Director -
John Craig Venter,
Director -
Peter Levy,
COO & Executive VP -
John Nosta,
Director -
Carl De Freitas,
Interim CFO -
Glen R. Fleischer,
Chief Executive Officer -
David J Matlin,
10% owner